Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely
May 10
Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedSep 07, 2024
DataAggregated Company Financials
Companies9
- 7D10.9%
- 3M18.5%
- 1Y-25.7%
- YTD-25.4%
The Life Sciences industry is up 11% in the last week, with Oxford Nanopore Technologies up 21%. Meanwhile, MaxCyte actually underperformed within the industry, shrinking 8.3% in the last week. In contrast, the industry has lost 26% in the last 12 months. As for the next few years, earnings are expected to grow by 19% per annum.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 08 Sep 2024 | UK£2.0b | UK£293.4m | -UK£192,317,721.90 | 12.2x | -10.4x | 6.8x |
| Tue, 06 Aug 2024 | UK£1.8b | UK£295.7m | -UK£190,046,673.15 | 11.9x | -9.3x | 6x |
| Thu, 04 Jul 2024 | UK£1.5b | UK£295.7m | -UK£190,047,404.49 | 11.5x | -8.1x | 5.2x |
| Sat, 01 Jun 2024 | UK£1.6b | UK£295.6m | -UK£189,808,553.55 | 11.3x | -8.6x | 5.5x |
| Mon, 29 Apr 2024 | UK£1.5b | UK£292.9m | -UK£189,020,345.45 | 7254.7x | -7.7x | 5x |
| Wed, 27 Mar 2024 | UK£1.8b | UK£295.9m | -UK£213,220,719.91 | 7353.7x | -8.4x | 6x |
| Fri, 23 Feb 2024 | UK£2.0b | UK£285.8m | -UK£189,230,023.72 | 6965.2x | -10.5x | 7x |
| Sun, 21 Jan 2024 | UK£2.9b | UK£450.2m | -UK£176,590,140.00 | 62.1x | -16.2x | 6.4x |
| Tue, 19 Dec 2023 | UK£3.1b | UK£450.2m | -UK£174,195,438.00 | 52.7x | -17.6x | 6.8x |
| Thu, 16 Nov 2023 | UK£3.0b | UK£455.8m | -UK£168,936,857.00 | 48.6x | -18x | 6.7x |
| Sat, 14 Oct 2023 | UK£2.9b | UK£458.8m | -UK£165,696,571.00 | 51.1x | -17.6x | 6.4x |
| Mon, 11 Sep 2023 | UK£3.1b | UK£440.5m | -UK£166,985,165.00 | 69.6x | -18.6x | 7x |
| Wed, 09 Aug 2023 | UK£3.4b | UK£476.6m | -UK£124,733,230.00 | 70.6x | -27x | 7.1x |
| Fri, 07 Jul 2023 | UK£2.9b | UK£476.6m | -UK£124,749,031.00 | 66.1x | -23.3x | 6.1x |
| Sun, 04 Jun 2023 | UK£3.3b | UK£477.0m | -UK£116,998,754.00 | 67.8x | -28.5x | 7x |
| Tue, 02 May 2023 | UK£3.1b | UK£479.9m | -UK£117,165,188.00 | 36.3x | -26.8x | 6.5x |
| Thu, 30 Mar 2023 | UK£2.8b | UK£459.1m | -UK£119,192,049.00 | 33.6x | -23.4x | 6.1x |
| Sat, 25 Feb 2023 | UK£3.1b | UK£444.0m | -UK£183,285,157.00 | 43.7x | -17x | 7x |
| Mon, 23 Jan 2023 | UK£3.4b | UK£442.7m | -UK£182,486,738.00 | 47.5x | -18.6x | 7.7x |
| Wed, 21 Dec 2022 | UK£3.4b | UK£443.4m | -UK£182,877,201.00 | 48.7x | -18.4x | 7.6x |
| Fri, 18 Nov 2022 | UK£3.6b | UK£447.9m | -UK£178,908,987.00 | 50.3x | -19.9x | 8x |
| Sun, 16 Oct 2022 | UK£3.5b | UK£449.2m | -UK£176,568,208.00 | 42.7x | -19.8x | 7.8x |
| Tue, 13 Sep 2022 | UK£3.7b | UK£365.6m | -UK£190,965,855.00 | 48.9x | -19.5x | 10.2x |
| Thu, 11 Aug 2022 | UK£4.0b | UK£366.2m | -UK£187,889,205.00 | 48.9x | -21.2x | 10.9x |
| Sat, 09 Jul 2022 | UK£3.9b | UK£366.7m | -UK£188,130,827.00 | 39.8x | -20.5x | 10.5x |
| Mon, 06 Jun 2022 | UK£3.8b | UK£360.3m | -UK£192,190,085.00 | 43x | -19.9x | 10.6x |
| Wed, 04 May 2022 | UK£5.0b | UK£922.8m | -UK£165,784,650.00 | 43.2x | -30.3x | 5.4x |
| Fri, 01 Apr 2022 | UK£6.7b | UK£929.6m | -UK£311,278,432.00 | 48.2x | -21.4x | 7.2x |
| Sun, 27 Feb 2022 | UK£7.1b | UK£891.2m | -UK£199,059,728.00 | 43.5x | -35.8x | 8x |
| Tue, 25 Jan 2022 | UK£7.4b | UK£849.2m | -UK£185,705,548.00 | 30.2x | -39.6x | 8.7x |
| Thu, 23 Dec 2021 | UK£9.7b | UK£849.5m | -UK£186,926,965.00 | 30.8x | -51.7x | 11.4x |
| Sat, 20 Nov 2021 | UK£9.1b | UK£843.7m | -UK£189,260,548.00 | 21.7x | -48.1x | 10.8x |
| Mon, 18 Oct 2021 | UK£7.9b | UK£819.7m | -UK£188,428,759.00 | 30.9x | -41.7x | 9.6x |
| Wed, 15 Sep 2021 | UK£3.1b | UK£674.8m | -UK£136,626,800.35 | 27.6x | -22.9x | 4.6x |
Price to Earnings Ratio
-22.9x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 24% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -2.40% | |
| Healthcare | -3.20% | |
| Life Sciences | 10.92% | |
| Clinical Research and Equipment | 10.92% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.42 | 21.1% +UK£232.5m | -34.7% | PS8x | |
| ERGO Ergomed | UK£13.46 | 0.1% +UK£14.7m | 3.5% | PE46.7x | |
| C4XD C4X Discovery Holdings | UK£0.12 | 45.9% +UK£9.5m | -16.4% | PE2.9x | |
| PRM Proteome Sciences | UK£0.034 | 2.4% +UK£236.1k | -45.3% | PS2x | |
| FAB Fusion Antibodies | UK£0.033 | 6.5% +UK£190.7k | -40.0% | PS2.8x |